Sulfur Nonionically Bonded Patents (Class 514/562)
-
Publication number: 20110288066Abstract: The present invention provides phenoxyacetic acid derivatives of Formula (I) for the treatment of CRTH2 related disorders and disease selected from asthma, atopic dermatitis and inflammatory dermatoses.Type: ApplicationFiled: February 9, 2010Publication date: November 24, 2011Applicant: MERCK SERONO S.A.Inventors: Stefano Crosignani, Catherine Jorand-Lebrun, Christophe Cleva, Adeline Pretre
-
Publication number: 20110288134Abstract: The present invention relates, in general, to fibroproliferative disorders, and, in particular, to a method of treating, preventing or reducing fibroproliferative disorders by administering to a mammal in need a composition comprising pharmacologically effective doses of a cytokine modifier, such as tranilast or pirfenidone, and an anti-oxidant which is a precursor of glutathione, such as N-acetyl-cysteine, or their pharmaceutically acceptable derivatives, salts, metabolites, or structural or functional analogues thereof.Type: ApplicationFiled: October 28, 2009Publication date: November 24, 2011Applicant: Pacific Therapeutics Ltd.Inventors: Lola Maksumova, Douglas Harry Unwin
-
Publication number: 20110281898Abstract: The invention relates to substituted phenoxyacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.Type: ApplicationFiled: July 26, 2011Publication date: November 17, 2011Inventors: Roger Victor Bonnert, Anil Patel, Stephen Thom
-
Publication number: 20110275635Abstract: Small molecule inhibitors of bacterial nicotinamide adenine dinucleotide synthetase (NADs), bacterial nicotinic acid mononucleotide adenylyltransferase (NaMNAT), and human nicotinamide mononucleotide adenylyltransferase (NMNAT) are provided, as well as methods of making and using the inhibitors.Type: ApplicationFiled: January 8, 2010Publication date: November 10, 2011Applicant: THE UAB RESEARCH FOUNDATIONInventors: Wayne J. Brouillette, Christie G. Brouillette, Whitney B. Moro
-
Patent number: 8053449Abstract: Various methods of administering medication(s) that inhibit the nonenzymatic formation of glycation and dehydration condensation complexes known as advanced glycation end-products (AGEs) or modulate the advanced glycation end-product receptor (RAGE) are provided. Also, a medication releasing medical devices, wherein at least a portion of the medical device releasably includes at least one of these medication(s) are provided.Type: GrantFiled: October 2, 2006Date of Patent: November 8, 2011Assignee: Cell Viable CorporationInventor: Jill D. Fabricant
-
Publication number: 20110268723Abstract: Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of inhibitors of the CCR3 receptor or its ligands eotaxin (CCL11), eotaxin-2 (CCL24) or eotaxin-3 (CCL26) inhibits ocular angiogenesis.Type: ApplicationFiled: July 7, 2011Publication date: November 3, 2011Applicant: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATIONInventor: Jayakrishna Ambati
-
Publication number: 20110269678Abstract: A method of improving nutrition and/or treating low grade inflammation in an elderly human subject comprises administering to said subject a cysteine source so as to provide metabolically available cysteine in the diet of said subject in a proportion relative to all available amino acids which is greater that the proportion of cysteine relative to all amino acids which corresponds to the requirements of a healthy young human subject.Type: ApplicationFiled: July 12, 2011Publication date: November 3, 2011Applicants: INSTITUT NATIONAL RECHERCHE AGRONOMIQUE, NESTEC S.A.Inventors: Denis Breuille, Sabine Mercier, Isabelle Papet, Philippe Patureau Mirand, Christiane Obled
-
Patent number: 8048923Abstract: The present invention relates to the treatment or prevention of neurodegenerative polyglutamine diseases by the administration of effective amounts of L-methionine S-sulfoximine, L-ethionine S-sulfoximine, glufosinate and/or branched chain ?-keto acids. In particular, the present invention relates to the treatment or prevention of Huntington's disease and other polyglutamine disorders caused by expanded genomic CAG nucleotides.Type: GrantFiled: January 16, 2004Date of Patent: November 1, 2011Assignee: Odessa PharmaInventor: William S. Brusilow
-
Publication number: 20110263580Abstract: This invention relates to a method for treating or preventing diseases associated with the deposition of ?-amyloid peptide in the brain, such as Alzheimer's disease, said method involving administration of a gamma-secretase inhibitor in an intermittent dosing regime to a patient in need thereof.Type: ApplicationFiled: December 4, 2009Publication date: October 27, 2011Inventor: Thomas Miller
-
Publication number: 20110251279Abstract: The task of this invention is in use of composition containing natural metabolites—amino acids, and in method of its administration which make it possible to increase skin repigmentation through sulfurcontaining compounds rise and activation of endogenic metabolic reactions, and to get persistent normalization of melanogenesis thus improving skin integument and as a consequence patient's quality of life. Composition includes L cystine, L glutamic acid and glycine in the following quantity, mg: L cystine 85 ± 10%, L glutamic acid 85 ± 10%, Glycine 85 ± 10% The amino acid composition mentioned above must be administered 3 times a day for 5 weeks independent of meal in accordance with method of increase of skin integument repigmentation in vitiligo. The course can be repeated in 4-5 weeks.Type: ApplicationFiled: April 28, 2011Publication date: October 13, 2011Applicant: NEKOMMERCHESKOE UCHREZHDNIE "NAUCHNO-ISSLEDOVATEL" SKU INSTITUT TSITOKHIMIIInventors: Irina Alekseevna KOMISSAROVA, Irina Markovna KORSUNSKAYA, Yaroslav Ryurikovich NARTSISSOV, Yaroslav Ryurikovich NARTSISSOV
-
Publication number: 20110250286Abstract: A system for the controlled release of one or more physiologically or pharmacologically active substances, comprising compositions in the form of micro particles or granules, particularly for use in the zootechnical and/or veterinary field. The micro particles include a core which contains one or more substances having a pharmacological action, food supplements or diagnostic media, said one or more substances being characterized by the presence, within their chemical structure, of a basic functional group, specifically including an amine functional group. The core comprises also one or more carboxylic acids and/or their salts and eventually one or more excipients. Said core is coated by an outer layer of fats or waxes, and preferably by a mixture of glyceride of fatty acids.Type: ApplicationFiled: April 7, 2011Publication date: October 13, 2011Applicant: KEMIN INDUSTRIES, INC.Inventors: Arduini Marcello, Arduini Lauro
-
Patent number: 8034799Abstract: Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) toxic, drug-induced, and metabolic (including hypertensive and/or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidneyType: GrantFiled: September 7, 2005Date of Patent: October 11, 2011Assignee: Philera New Zealand LimitedInventors: Garth J. S. Cooper, John R. Baker
-
Publication number: 20110245342Abstract: The invention regards the use of triiodothyronine sulfate, commonly named T3S, as a medicament having thyromimetic activity for the treatment of pathologies due to organic deficiency of triiodothyronine (T3), as such or in association with thyroxine (T4), and pharmaceutical formulations for oral administration thereof.Type: ApplicationFiled: April 8, 2011Publication date: October 6, 2011Applicant: Bracco S.p.A.Inventors: Aldo PINCHERA, Ferruccio Santini, Giovanni Rivolta, Livio Cavalieri, Fulvia Vella, Federico Maisano
-
Publication number: 20110245343Abstract: Provided are anti-wrinkle agents having a novel scaffold that is suitable as components for external skin preparations such as cosmetics. The anti-wrinkle agents comprise compounds represented by general formula (1), stereoisomers thereof, or pharmacologically acceptable salts thereof. Said anti-wrinkle agents have excellent efficacy in improving wrinkles and sagging that are caused by skin aging with increased age or occur as a result of photoaging due to ultraviolet rays exposure. [In the formula, R1 represents a hydrogen atom or a 1 to 8 carbon straight or branched alkyl group. R2 represents —SH, —SO3H, —S—S—X1, —S—X2, —SO—X3, —SO2—X4, —SO2—NY1—X5 or —SO2—NY2—Y3. X1-X5 independently are hydrogen atoms or 1 to 8 carbon aliphatic hydrocarbon groups or 5 to 12 carbon aromatic moiety wherein carbon atoms may be substituted with heteroatoms. Y1 to Y3 independently represent hydrogen atoms or 1 to 8 carbon linear or branched alkyl groups.Type: ApplicationFiled: November 12, 2009Publication date: October 6, 2011Inventors: Noriko Suenobu, Chihiro Kondo, Takashi Yamasaki
-
Publication number: 20110245158Abstract: The present disclosure relates to high protein dietary supplements for treating various symptoms and diseases associated with protein deficiency including weight gain, obesity, catabolic diseases, fibromyalgia, anxiety reactions, posttraumatic stress and chronic fatigue syndrome. Embodiments of dietary supplements comprise combinations of proteins, essential and semi-essential amino acids including L-Lysine, L-Arginine, and/or L-Histidine.Type: ApplicationFiled: June 20, 2011Publication date: October 6, 2011Inventor: George Scheele
-
Publication number: 20110244045Abstract: The present invention provides a controlled-release composition which provides a therapeutically effective plasma concentration of N-acetylcysteine over prolonged period of time. The present invention also includes the use of the controlled-release composition, either alone or in combination with at least one additional active agent, for reduction of vascular inflammation marker and treatment of diseases, conditions, and/or symptoms associated with systemic and/or vascular inflammation in a patient. Furthermore, the present invention provides a process of making granules comprising N-acetylcysteine, or a salt, solvate, prodrug, and/or analog thereof.Type: ApplicationFiled: May 11, 2009Publication date: October 6, 2011Applicant: TIARA PHARMACEUTICALS ,INC.Inventors: Yadon Arad, Liang C. Dong
-
Publication number: 20110245313Abstract: The present invention relates to compositions suitable for the treatment of pathological conditions distinguished by insufficient or reduced mitochondrial function. The compositions comprise, as principal active ingredients, the amino acids leucine, isoleucine and valine. The compositions may also comprise, as further active ingredients, amino acids threonine and lysine, and optionally, histidine, phenylalanine, methionine, tryptophan, as well as tyrosine and cysteine.Type: ApplicationFiled: June 15, 2011Publication date: October 6, 2011Applicant: PROFESSIONAL DIETETICS S.r.I.Inventor: Francesco Saverio DIOGUARDI
-
Publication number: 20110245312Abstract: The present invention relates to compositions suitable for the treatment of pathological conditions distinguished by insufficient or reduced mitochondrial function. The compositions comprise, as principal active ingredients, the amino acids leucine, isoleucine and valine. The compositions may also comprise, as further active ingredients, amino acids threonine and lysine, and optionally, histidine, phenylalanine, methionine, tryptophan, as well as tyrosine and cysteine.Type: ApplicationFiled: June 15, 2011Publication date: October 6, 2011Applicant: PROFESSIONAL DIETETICS S.r.I.Inventor: Francesco Saverio DIOGUARDI
-
Publication number: 20110237672Abstract: The invention deals with the use of cysteine, a cysteine precursor substance or a cysteine derivative or a cysteine-containing substance to increase the oxygen supply to the tissue by increasing the ventilatory activity and/or by increasing the production of the blood-forming hormone erythropoietin (EPO), especially for the treatment of aging-related or disease-related conditions associated with a decreased oxygen supply to the tissue, especially in elderly subjects, in the treatment of malignant diseases and in cardiorespiratory diseases.Type: ApplicationFiled: June 8, 2011Publication date: September 29, 2011Applicant: 2458781 CANADA INC.Inventor: Wulf Dröge
-
Publication number: 20110236395Abstract: Inhibitors of matrix metalloproteinase 2 are used to treat or prevent a fibrotic disorder of the posterior capsule of the eye, for example posterior capsule opacification (PCO), or of a tissue or structure of the eye other than the lens or capsular bag.Type: ApplicationFiled: September 9, 2009Publication date: September 29, 2011Applicant: UNIVERSITY OF EAST ANGLIAInventors: Ian Michael Wormstone, Lucy Dawes, Julie Ann Eldred, Dylan Edwards, Lisa Hodgkinson
-
Publication number: 20110236508Abstract: A formulation comprising large quantities of l-arginine and/or fat plaque dissolving agents which is palatable, stench free, and does not evoke nausea. The formulation is adapted to facilitate the adsorption of l-arginine to the blood system and to introduce high levels of l-arginine and/or other fat plaque dissolving agents such as EDTA, its derivatives or its salts into the blood system which are sufficient for effectively dissolving fat plaques in the artery. The formulation comprises at least 10% (w/w) L-arginine, edible organic acids, emulsifier(s), preservatives, flavorings, ethanol and water.Type: ApplicationFiled: November 30, 2009Publication date: September 29, 2011Inventors: Benzion Geshuri, Orna Levin
-
Publication number: 20110237671Abstract: Disclosed is a method of using a composition comprising vitamin U as an active ingredient to heal skin wound and inhibit collagenase. The method includes the step of applying an effective amount of the composition on human skin. The vitamin U is included at a concentration of 0.00001-30.0% (w/w) by the total weight of the composition.Type: ApplicationFiled: June 3, 2011Publication date: September 29, 2011Applicant: CUSKIN CO., LTD.Inventors: Hyung Geun MIN, Won Serk KIM
-
Publication number: 20110237554Abstract: Inhibitors of NKCC1, such as bumetanide, when coadministered with inhibitors of GABA transaminase, such as vigabatrin, attenuate both the retinal toxicity and the intramyelinic edema.Type: ApplicationFiled: March 22, 2011Publication date: September 29, 2011Inventor: Frances E. Jensen
-
Patent number: 8026280Abstract: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy. Carboxylic acid-containing compounds having a terminal cyclic moiety, a carboxylic acid group, and a C3-12 hydrocarbon chain optionally containing at least one double bond, at least one triple bond, or at least one double bond and one triple bond linking the cyclic moiety and the carboxylic acid group are inhibitors of histone deacetylase.Type: GrantFiled: December 26, 2001Date of Patent: September 27, 2011Assignee: Errant Gene Therapeutics, LLCInventors: Hsuan-Yin Lan-Hargest, Robert J. Kaufman, Norbert L Wiech
-
Publication number: 20110224156Abstract: The invention relates to propionic acids, propionic acid esters, and related compounds, pharmaceutical compositions containing these compounds, and methods of using these compounds for the treatment of various diseases or conditions, including but not limited to diseases and/or conditions of Central Nervous System (CNS).Type: ApplicationFiled: March 8, 2011Publication date: September 15, 2011Inventors: Mark A. Wolf, Keith D. Barnes
-
Publication number: 20110217364Abstract: A modification of pharmacokinetics of suramin by use of amino compounds in modification of lipophilicity and protein binding characteristics for tackling the physico-chemical properties of suramin that gives it poor distribution in the body; formulating the resulting product in a form that leads to targeting body fluids like the lymphatic system when administered in a specific way; and determining the route of administration that maximizes targeting with a view to reducing the dosage so as to limit toxicity, hence increase tolerance by patient.Type: ApplicationFiled: July 10, 2009Publication date: September 8, 2011Inventor: Sammy O. Opiyo
-
Publication number: 20110212188Abstract: Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) toxic, drug-induced, and metabolic (including hypertensive and/or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidneyType: ApplicationFiled: February 28, 2011Publication date: September 1, 2011Inventors: GARTH J.S. COOPER, John R. Baker
-
Publication number: 20110207749Abstract: The present disclosure is generally directed to compounds that can inhibit DAGL? and/or ? activity, compositions comprising such compounds, and methods for inhibiting DAGL? and/or ? activity.Type: ApplicationFiled: February 11, 2011Publication date: August 25, 2011Inventors: Louis S. Chupak, Xiaofan Zheng, Min Ding, Shuanghua Hu, Yazhong Huang, Robert G. Gentles
-
Publication number: 20110206638Abstract: The disclosure provides compositions and methods for reducing the mutation rate of a virus, such as an RNA virus or a DNA virus, in a cell infected with the virus by, in one aspect, contacting the cell with an effective amount of an iron chelator or an antioxidant. Also provided are compositions and methods for enhancing the efficacy of an agent or a therapy directed at a virus.Type: ApplicationFiled: January 19, 2011Publication date: August 25, 2011Inventor: Jinah Choi
-
Publication number: 20110206781Abstract: Described herein are methods, compositions and kits related to manipulating hematopoietic stem cells (HSC) and more particularly to methods, compositions and kits related to increasing the number of hematopoietic stem cells in vitro, ex vivo and/or in vivo. Also described are methods, compositions and kits related to making an expanded population of HSC and methods, compositions and kits related to using the expanded population of HSC. For example, HSC growth may be enhanced by contacting the nascent stem cells or HSC with an agent that stimulates the nitric oxide signaling pathway.Type: ApplicationFiled: May 28, 2009Publication date: August 25, 2011Inventors: Leonard I. Zon, Trista E. North, Wolfram Goessling
-
Patent number: 8003696Abstract: The present invention is directed to compositions and methods of treating bacterial, viral, fungal diseases; inflammation or inflammatory-related disorders; pain; and skin conditions. The composition comprises an organic solvent extract, which is prepared by the method comprising the steps of: (a) mixing methionine with water, (b) adding an aqueous hypochlorite solution to the methionine solution and mixing, (c) adding a water-immiscible organic solvent to (b) and mixing, and (d) separating the organic solvent phase from the water phase to obtain the organic solvent extract. The present invention is also directed to a method for preparing the organic solvent extract.Type: GrantFiled: September 3, 2008Date of Patent: August 23, 2011Assignee: Olatec Industries LLCInventor: Christopher Torrence
-
Patent number: 8003134Abstract: An ascorbic acid-based composition and related method for the treatment of aging or photo-damaged skin is disclosed. The composition includes water and ascorbic acid, at least a portion of which has generally been pretreated by being dissolved under relatively high temperature and concentration conditions. The composition typically includes at least about 5.0% (w/v) ascorbic acid and may advantageously be formulated to have a pH above 3.5. Generally, the composition also includes non-toxic zinc salt, tyrosine compound, and/or pharmaceutically acceptable carrier. In addition, the composition may include an anti-inflammatory compound, such as aminosugar and/or sulfur-containing anti-inflammatory compound. The topical composition may be in the form of a serum, a hydrophilic lotion, an ointment, a cream, or a gel.Type: GrantFiled: November 21, 2001Date of Patent: August 23, 2011Assignee: Bioderm, Inc.Inventor: Lorraine Faxon Meisner
-
Publication number: 20110201563Abstract: The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) through a linker and optionally, a connector molecule.Type: ApplicationFiled: May 13, 2009Publication date: August 18, 2011Applicant: YALE UNIVERSITYInventors: David Spiegel, Ryan Murelli, Andrew Zhang
-
Publication number: 20110201576Abstract: The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S3I-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis.Type: ApplicationFiled: February 4, 2011Publication date: August 18, 2011Applicants: H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, University of Central FloridaInventors: James Turkson, Said M. Sebti, Wayne Guida, Man Lun Yip, Nicholas J. Lawrence, Harshani Lawrence, Benjamin Greedy
-
Publication number: 20110201675Abstract: The invention includes compositions and methods of treatment of cancers susceptible to treatment with nucleotide analog chemotherapeutic agent, including cancers in which nucleotide analog resistant tumors have developed, including identifying a subject having cancer susceptible to treatment with a nucleotide analog chemotherapeutic agent and a mitotic disruptor/polo-like kinase (Plk) pathway inhibitor to a subject; and monitoring the subject for a reduction or stabilization of at least one sign or symptom of cancer.Type: ApplicationFiled: April 17, 2008Publication date: August 18, 2011Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Antonio Jimeno, Manuel Medina Hidalgo
-
Publication number: 20110195945Abstract: Compositions and methods of treating or preventing disease or injury to a human patient or biological material undergoing ischemic or hypoxic conditions.Type: ApplicationFiled: February 11, 2011Publication date: August 11, 2011Applicant: Ikaria, Inc.Inventors: Fuqiang Ruan, Edward A. Wintner, Thomas L. Deckwerth
-
Publication number: 20110195967Abstract: Selected 2-arylacetic acids, their derivatives and pharmaceutical compositions that contain these compounds are useful in inhibiting chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2 membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from their activation. In particular, 2(ortho)-substituted arylacetic acids or their derivatives, such as amides and sulfonamides, lack cyclo-oxygenase inhibition activity and are particularly useful in the treatment of neutrophil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.Type: ApplicationFiled: April 22, 2011Publication date: August 11, 2011Applicant: DOMPE PHA.R.MA S.P.A.Inventors: Alessio MORICONI, Marcello ALLEGRETTI, Maria Candida CESTA, Riccardo BERTINI, Cinzia BIZZARRI, Francesco COLOTTA
-
Publication number: 20110190302Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-phenylene compounds of the following formula (I) (collectively referred to herein as “APSAP compounds”).Type: ApplicationFiled: September 18, 2009Publication date: August 4, 2011Applicant: PIMCO 2664 LIMITEDInventors: Iain Robert Greig, Rose Mary Sheridan, Raymond Fisher, Matthew John Tozer, Juha Andrew Clase, Andrew Smith, Andrew Robert Tuffnell, Robert Jurgen Van 't Hof
-
Publication number: 20110183016Abstract: The present invention is directed to liquid compositions containing chitosan, a chitosan derivative or a physiologically acceptable salt thereof, which form a film after application onto the scalp and/or the hair, which compositions are useful for delivery of actives onto the scalp surface and/or onto the hair.Type: ApplicationFiled: February 4, 2011Publication date: July 28, 2011Applicant: POLICHEM SAInventors: Federico Mailland, Emanuela Mura
-
Publication number: 20110184006Abstract: A thermally stable Vitamin C composition containing montmorillonite, an organic acid containing L-ascorbic acid or a derivative thereof, a divalent cation present within nanolayers of the montmorillonite, wherein the organic acid is combined with the divalent cation within the nanolayers to form an organic acid-montmorillonite chelate.Type: ApplicationFiled: January 28, 2010Publication date: July 28, 2011Applicant: NATIONAL RESEARCH COUNCIL OF SRI LANKAInventors: Chandhi S. Goonesekara, Vajira Seneviratne, D. Nedra Karunaratne, Veranja Karunaratne
-
Patent number: 7985767Abstract: Compounds of the formula are disclosed herein. Therapeutic methods, compositions, and medicaments related thereto are also disclosed.Type: GrantFiled: September 6, 2007Date of Patent: July 26, 2011Assignee: Allergan, Inc.Inventors: David W. Old, Robert M. Burk, Todd S. Gac
-
Publication number: 20110178087Abstract: The present invention provides novel compounds and pharmaceutical compositions thereof, as well as methods for using the compounds and pharmaceutical compositions for treating tumors. Examples of specific tumor types that the compounds may be used to treat include, but are not limited to sarcomas, melanomas, neuroblastomas, carcinomas (including but not limited to lung, renal cell, ovarian, liver, bladder, and pancreatic carcinomas), and mesotheliomas.Type: ApplicationFiled: March 30, 2011Publication date: July 21, 2011Applicant: Compass Pharmaceuticals LLC.Inventors: David Kanne, John Ward, Gary Look, X. Michael Wang, Diva Chan, Tina Lee, Donald R. James, Richard Gless, John Schullek, Charles Vacin
-
Publication number: 20110177000Abstract: The present invention is directed to a method of treating disordered control of breathing including the treatment of apnea and hypoventilation associated with congenital or acquired brain stem abnormalities. Specifically the invention is directed to treating disordered control of breathing by administering an S-nitrosylating agent selected from the group consisting of ethylnitrite, glutathione, nitric oxide, S-nitrosocysteine, S-nitrosoglutathione, S-nitroso-L-cysteinyl glycine, N-acetyl cysteine and S-nitroso-N-acetyl cysteine. As shown in FIG. 1C the ability of endogenous SNOs to increase VE in freely behaving, conscious rats using whole-body plethysmography revealed that CSNO, GSNO and CGSNO (1 nmol each) caused equivalent increases in VE, whereas D-CSNO had no effect (left bar graph is the control whereas the right bar represents administration of the respective SNO).Type: ApplicationFiled: March 28, 2011Publication date: July 21, 2011Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Benjamin M. Gaston, David Gozal
-
Patent number: 7981915Abstract: This invention features methods for treating diseases associated with mutations in the CFTR gene by administering PPAR agonists, specifically PPAR?, PPAR?, and PPAR? agonists, PPAR inducers, and/or antioxidants. Also disclosed are screening methods for identifying therapeutically useful candidate compounds.Type: GrantFiled: October 31, 2005Date of Patent: July 19, 2011Assignee: Beth Israel Deaconess Medical CenterInventor: Steven D. Freedman
-
Publication number: 20110171296Abstract: The object of the invention is the use of compounds comprising one or more free sulphhydryl or amino groups for preparing a pharmaceutical composition for locally binding acetaldehyde in saliva, the stomach or the large intestine, and pharmaceutical compositions comprising the said compounds.Type: ApplicationFiled: January 11, 2011Publication date: July 14, 2011Applicant: Biohit OyjInventors: Mikko Salaspuro, Martti Marvola
-
Publication number: 20110171193Abstract: Provided herein are methods and materials for treating pulmonary hypertension (PH) in a subject. Also provided herein is a method of diagnosing whether a has PH by detecting a PH marker. A PKG pulmonary hypertension marker has been identified and may be useful in predicting PH disease progression and assessing a subject's response to PH therapy.Type: ApplicationFiled: June 12, 2009Publication date: July 14, 2011Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: You-Yang Zhao, Asrar B. Malik
-
Publication number: 20110171187Abstract: The present invention provides a dietary supplement that promote the growth, repair, and maintenance of mammalian bone and joint connective tissue. In particular, the dietary supplement comprises a combination of at least one metal chelate and at least one chondroprotective agent.Type: ApplicationFiled: May 30, 2008Publication date: July 14, 2011Applicant: Novus International, Inc.Inventors: Jeremy D. Moore, Thomas R. Hampton, Robert Harrell
-
Publication number: 20110172171Abstract: The present invention relates to taurine or taurine-like substances for the prevention of brain oedema, particularly brain intramyelinic oedema and more particularly brain intramyelinic oedema induced by an anti-convulsive drug such as vigabatrin. The invention relates to a substance selected from the group consisting of taurine, a taurine precursor, a taurine metabolite, a taurine derivative, a taurine analog and a substance required for the taurine biosynthesis for the prevention of brain oedema.Type: ApplicationFiled: September 4, 2009Publication date: July 14, 2011Inventors: Serge Picaud, José-Alain Sahel, Firas Jammoul
-
Publication number: 20110165264Abstract: Use of cilastatin to reduce the nephrotoxicity of different compounds. The invention refers to use of cilastatin to prepare a medicinal product to reduce the nephrotoxicity of a nephrotoxic compound that enters the cells of the proximal tubule through cholesterol rafts. The invention is based on the discovery that a great number of nephrotoxic compounds, including drugs, enter the cells of the proximal tubule through the cholesterol rafts, and that cilastatin is able to interfere with this transport mechanism, decreasing the nephrotoxicity of such compounds to a variable extent. The nephroprotective effect is common to compounds of different chemical nature and solubility and is specific for the kidney, causing no interference with the effects of nephrotoxic drugs having their targets in other organs. Therefore, administration of cilastatin allows for decreasing the nephrotoxic effects of different drugs without reducing their therapeutic effects.Type: ApplicationFiled: July 11, 2008Publication date: July 7, 2011Inventors: Alberto Tejedor Jorge, Alberto Lazaro Fernandez, Sonia Camaño Paez, Ana Maria Torres Redondo, José Antonio Lazaro Manero, Manuela Castilla Barba, Maria del Carmen De Lucas Collantes
-
Patent number: RE42645Abstract: Nutritional or therapeutic compositions containing glutamic acid, cystine, glycine and a selenium precursor and methods for their utilization to increase glutathione synthesis and thereby enhance the immune system are described.Type: GrantFiled: March 9, 2006Date of Patent: August 23, 2011Inventor: Albert Crum